Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41,389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor.
He LN, Chen T, Fu S, Jiang Y, Zhang X, Chen C, Du W, Luo L, Li A, Wang Y, Yu H, Zhou Y, Wang Y, Yang Y, Huang Y, Zhao H, Fang W, Zhang L, Hong S. He LN, et al. Among authors: jiang y. Ther Adv Med Oncol. 2023 Oct 24;15:17588359231200463. doi: 10.1177/17588359231200463. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37881238 Free PMC article.
Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
He LN, Fu S, Zhang X, Hu Q, Du W, Li H, Chen T, Chen C, Jiang Y, Zhou Y, Lin Z, Yang Y, Huang Y, Zhao H, Fang W, Zhang L, Hong S. He LN, et al. Among authors: jiang y. Lung Cancer. 2021 Aug;158:1-8. doi: 10.1016/j.lungcan.2021.05.030. Epub 2021 May 28. Lung Cancer. 2021. PMID: 34087538
Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.
He LN, Chen T, Fu S, Chen C, Jiang Y, Zhang X, Du W, Li H, Wang Y, Ali WAS, Zhou Y, Lin Z, Yang Y, Huang Y, Zhao H, Fang W, Zhang L, Hong S. He LN, et al. Among authors: jiang y. Lung Cancer. 2022 Mar;165:10-17. doi: 10.1016/j.lungcan.2021.12.015. Epub 2021 Dec 31. Lung Cancer. 2022. PMID: 35051754
A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatment.
Jiang Y, Wang Y, Fu S, Chen T, Zhou Y, Zhang X, Chen C, He LN, Du W, Li H, Lin Z, Zhao Y, Yang Y, Zhao H, Fang W, Huang Y, Hong S, Zhang L. Jiang Y, et al. Thorac Cancer. 2022 Jun;13(11):1558-1569. doi: 10.1111/1759-7714.14386. Epub 2022 Apr 18. Thorac Cancer. 2022. PMID: 35437945 Free PMC article. Clinical Trial.
Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer.
Wang Y, Fu S, Zhang X, Du W, Luo L, Jiang Y, Zhou Y, Zhao Y, Yang Y, Zhao H, Fang W, Huang Y, Zhang L, Hong S. Wang Y, et al. Among authors: jiang y. Front Immunol. 2023 May 29;14:1151385. doi: 10.3389/fimmu.2023.1151385. eCollection 2023. Front Immunol. 2023. PMID: 37313402 Free PMC article.
Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy.
He LN, Li H, Du W, Fu S, Luo L, Chen T, Zhang X, Chen C, Jiang Y, Wang Y, Wang Y, Yu H, Zhou Y, Lin Z, Zhao Y, Huang Y, Zhao H, Fang W, Yang Y, Zhang L, Hong S. He LN, et al. Among authors: jiang y. iScience. 2023 Jun 7;26(7):107058. doi: 10.1016/j.isci.2023.107058. eCollection 2023 Jul 21. iScience. 2023. PMID: 37416452 Free PMC article.
Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy.
Sun T, Huang S, Jiang Y, Yuan H, Wu J, Liu C, Zhang X, Tang Y, Ben X, Tang J, Zhou H, Zhang D, Xie L, Chen G, Zhao Y, Wang S, Xu H, Qiao G. Sun T, et al. Among authors: jiang y. Front Bioeng Biotechnol. 2022 Oct 6;10:1010672. doi: 10.3389/fbioe.2022.1010672. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36277407 Free PMC article.
41,389 results
You have reached the last available page of results. Please see the User Guide for more information.